Showing 15 posts of 1050 posts found.


Phase III trial of Libtayo stopped early after positive overall survival results

March 15, 2021
Sales and Marketing Cancer, Libtayo, Regeneron, Sanofi

A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be stopped early after positive results demonstrated …

Complix and I-Mab sign deal to develop alphabody cancer therapies

March 11, 2021
Cancer, Complix, oncology

Biopharmaceutical company Complix has signed a drug discovery deal with I-Mab Biopharma, a clinical-stage company focused on the discovery, development, …


Lilly’s cancer drug Retsevmo gets UK approval for multiple indications

March 10, 2021
Research and Development Cancer, Eli Lilly, MHRA

The MHRA has granted conditional marketing authorisation for Eli Lilly’s Retsevmo (selpercatinib) as monotherapy for a number of cancer indications.


Novartis’ canakinumab fails to improve lung cancer survival in Phase III study

March 9, 2021
Manufacturing and Production Cancer, Novartis, lung cancer

Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …


Roche voluntarily withdraws Tecentriq’s US bladder cancer indication

March 8, 2021
Sales and Marketing Cancer, Roche, bladder cancer, tecentriq

Roche has announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial …


Amgen to acquire Five Prime Therapeutics for approximately $1.9bn

March 5, 2021
Medical Communications Amgen, Cancer, five prime

Amgen has announced it will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of …

Hong Kong Baptist University researchers develop drug for EBV-associated cancers

March 4, 2021
Cancer, Epstein-barr virus, Hong Kong

Researchers at Hong Kong Baptist University have developed a novel drug with the potential to become a next-generation treatment for …

Cancer Research UK joins forces with Teon to develop new cancer drug

March 2, 2021
Manufacturing and Production Cancer, Cancer Research UK, Teon

Cancer Research UK and Teon Therapeutics have entered a collaboration agreement to progress the early phase clinical development of Teon’s new cancer drug. The partnership …

Oasmia acquires rights to cancer drug candidate Cantrixil in $44m deal

March 1, 2021
Sales and Marketing Cancer, Kazia, Oasmia

Oasmia Pharmaceutical, an innovation-focused specialty pharmaceutical company, is set to acquire exclusive global development rights for Kazia Therapeutics’ ovarian cancer …

Ipsen receives CHMP recommendation for Cabometyx in combination with Opdivo

March 1, 2021
Sales and Marketing Cancer, EMA, ipsen

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Ipsen’s Cabometyx (cabozantinib) in combination with …

NICE recommends Novartis’ ribociclib in combination with fulvestrant for breast cancer

February 26, 2021
Medical Communications Cancer, NICE, Novartis

NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …

New research article confirms role of masitinib as a potential pancreatic cancer therapy

February 25, 2021
AB Sciences, Cancer, masitinib

A recently published, peer-reviewed research article has concluded that the inhibition of mast cells with AB Science’s masitinib could represent …


FDA approves Regeneron & Sanofi’s Libtayo for advanced non-small cell lung cancer

February 23, 2021
Manufacturing and Production Cancer, Sanofi

The FDA has approved Regeneron & Sanofi’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) for the first-line treatment of patients with advanced non-small …

ONK and Anthony Nolan combine forces to work on blood cancer therapies

February 22, 2021
Sales and Marketing Anthony Nolan, Cancer, ONK, blood cancer, cancer treatment

ONK Therapeutics and blood cancer charity Anthony Nolan will work together on therapies for patients with haematological malignancies (blood cancers) …


MaxiVAX and Minaris sign manufacturing deal for cell-based cancer immunotherapy

February 22, 2021
Sales and Marketing Cancer, MaxiVAX, Minaris

MaxiVAX and Minaris Regenerative Medicine have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of …

Latest content